李秀艳博士

汇智协和公司 创始人,首席执行官

前强生(J&J)全球创新合作战略联盟 全球总监

    李秀艳博士专长以多方合作尤其是跨境合作的方式开发上市高价值的医药健康产品。她领导的汇智协和专注帮助中国企业国际化,转让其产品的国际权益及建立适宜的境外销售渠道,并帮助中国企业境内境外寻找合适的产品技术或合作伙伴。李秀艳博士获美国康州大学药学博士,之前获北京大学化学系学士和硕士学位。曾任职Honeywell, AMRI, Covidien, J&J 强生,方达,药明康德等多家国内国外知名企业。 职涯前12年迅速从一线研发科学家成长为跨界产品创新的领军人,直接领导并参与了多个新药,仿制药,大健康产品,辅料,高纯试剂及材料的开发,包括生产工艺开发,分析方法开发,中试生产,及大规模生产的技术转移。中期6年在国际知名的健康产品开发公司强生负责产品的全球外包生产和新剂型产品的创新合作,外包产品价值2.5亿美元,合作开发产品管线价值10亿美元。得益于与超过200多家的CRDMO, DDS, Biotech and pharma企业的交流访问及合作,积累了丰富的技术评估,外包或供应商尽职调查,合同洽谈的经验。近5年供职中美著名外包服务企业,领导在中国的产品开发申报的服务,向中国引进先进的医疗健康产品和技术,帮助中国企业国际化,更深刻地理解了中国市场和企业的需求。2015年底合伙创立汇智协和。她还兼任世中联经皮给药专业委员会会副主席,儿童产品联盟筹委会委员。

Dr. Cheryl Li, currently CEO and CO-founder of PharmaSynergy, was honored to have served in several reputable CRDMO, global pharmaceutical and consumer product companies including Wuxi Apptec, J&J, Covidien, AMRI. She has over 20 years in-depth industry experience with increasing responsibilities in a wide range of professional areas including product development (API and FGs), R&D outsourcing, external manufacturing, product in-licensing and strategic partnership, product due diligence, and business contract negotiation. She had assessed more than 200 CRO/CMO and DDS firms as well as API and Packaging companies globally and is familiar with how the businesses are conducted in different parts of the world. She received her Ph.D. degree in Pharmaceutical Sciences from UCONN, MS and BS degrees in Chemistry from Peking University. She has been widely involved in various professional organizations, currently serving as VP of China Transdermal Society and the Organizing Committee member for Children’s Products Association.

鲁礼炎

隆安律师事务所 合伙人/执业律师、专利代理人

        隆安律师事务所合伙人/执业律师、专利代理人,鲁律师先后就读于华东政法大学法律学院、上海交通大学药学院。拥有法学、药学等领域的复合背景,擅长医药领域创新成果知识产权保护、医药创新技术成果转化、医药项目投融资及CFDA/FDA政策咨询等。曾主持某505B(2)新药项目的投融资及中美双报评估;主办某药品配方商业秘密侵权案(涉案标的约1亿)、某创新生物药企基因测序专利技术B轮融资项目(融资规模1.2亿)、上海交大某创新制剂专利复审、某上市公司知识产权战略规划等;并为多家医药上市公司进行国际专利布局,为国内外多家高科技企业提供知识产权保护及投融资服务,具有多家新药高科技初创公司成果转化及融资经验。

        隆安成立于1992年,是中国最早的合伙制律师事务所之一, 现有员工人数约1200人。在过去的二十五年里,隆安为包括世界500强在内的众多大中型企业提供了并购、金融、外商直接投资、知识产权、大型项目等领域的法律服务。隆安多次被全国律师管理机构评为中国最为优秀的律师事务所之一。凭借近年来的整体实力,隆安成功入围《亚洲法律杂志》年度多项法律大奖,入选中国十佳成长律所,并以前十的成绩荣登亚洲最大50家律所及中国律所30强榜单。隆安亦在英国《律师》杂志亚太地区百强律所榜单及中国精英律所30强榜单中位居前列。

Mr. Lu Liyan is the partner, lawyer and patent lawyer of Long An Law Firm. Lawyer Lu studied law at East China University of Political Science and Law and studied Pharmaceutical Engineering at Shanghai Jiao Tong University, thus possessing a complex background in law and pharmacy. Lawyer Lu is good at protection of intellectual property involving innovative achievements in the field of medicine, transformation of medical innovative technology achievements, investment and financing of pharmaceutical projects and consultation of CFDA / FDA policy. Lawyer Lu has presided over the investment & financing of a 505B (2) new drug project as well as the evaluation conference of the US-Chinese Application regarding the new drug; has dealt with an infringement of commercial secret regarding a drug formulation; has undertook a B round of financing regarding an innovative biopharmaceutical company's gene sequencing patent; has acted for the reexamination of an innovative formulations patent of Shanghai Jiao Tong University; has designed the intellectual property strategic planning of a listed company; has designed the international patent portfolio for many listed pharmaceutical companies; has been providing services involving the protection of intellectual property and investment & financing for many high-tech enterprises at home and abroad; and experienced in financing and transforming the achievements of many newly established high-tech companies.